Investigational Drug Information for Entinostat
✉ Email this page to a colleague
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 70 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
Summary for Entinostat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,766 |
| WIPO Patent Applications | 1,146 |
| Japanese Patent Applications | 447 |
| Clinical Trial Progress | Phase 2 (2014-03-29) |
| Vendors | 120 |
Recent Clinical Trials for Entinostat
| Title | Sponsor | Phase |
|---|---|---|
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
